Staging, grading and risk groups for prostate cancer

Doctors look at test results and at what the cells look like under a microscope to find out the stage, grade and risk group of the cancer. This helps your doctors plan the best treatment.

Staging of prostate cancer

The stage of a cancer describes its size and how far it has spread. The results of your tests help your doctors determine the stage.

Doctors often use the TNM staging system for prostate cancer.

We understand that waiting to know the stage and grade of your cancer can be a worrying time. Staging and grading of prostate cancer can be complicated. We're here if you need someone to talk to. You can:

TNM staging system

T describes the size of the tumour in the prostate gland.

N describes whether the cancer has spread to any lymph nodes (N). N0 means the cancer has not spread to the lymph nodes. Early prostate cancer is always N0. N1 means there is cancer in 1 or more lymph nodes close by.

M describes whether the cancer has spread to another part of the body. This is called metastatic cancer. M0 means the cancer has not spread to another part of the body. Early and locally advanced prostate cancer are always M0.

T – Tumour

T1 – the tumour is within the prostate. It is too small to be felt during a digital rectal examination or seen on a scan. Your surgeon may find cancer if you have surgery for another reason – for example, an enlarged prostate. T1 tumours are divided into:

  • T1a – the cancer is found in 5% or less of the tissue removed
  • T1b – the cancer is found in more than 5% of the tissue removed
  • T1c – the cancer is found by a needle biopsy, which was done because of a raised PSA level.

T2 – the tumour is within the prostate. A doctor can feel it when they do a digital rectal examination. The tumour can also be seen on a scan.

T1 and T2 tumours are not likely to affect the lymph nodes or spread to other parts of the body. Doctors call this early or localised prostate cancer.

T3 tumours have spread outside the prostate capsule. T3 tumours are divided into:

  • T3a – the tumour has spread through the capsule on 1 or both sides of the prostate
  • T3b – the cancer has spread to the seminal vesicles.

T4 tumours have spread outside the prostate and may be growing into tissues or organs close by. If the cancer has not spread to another part of the body, such as the bones, it is called locally advanced prostate cancer.

When the cancer has spread to another area, it is called advanced or metastatic prostate cancer.

T3 and T4 cancers are called locally advanced prostate cancer.

You can contact your doctor or specialist nurse about your TNM staging. They can explain it to you.

Grading prostate cancer

The grade of a cancer describes:

  • how the cancer cells look
  • how likely they are to grow and spread outside the prostate.

Doctors will take several samples of the cancer cells during a biopsy. Then they will look at these samples under a microscope.

Grade Groups are a system to describe the grade of a prostate cancer. They are based on the Gleason score.

Gleason score

The Gleason score looks at the pattern of cancer cells in the prostate tissue, and how different they are to normal prostate cells.

There are 5 different patterns, graded from 1 to 5. Grades 1 and 2 look like normal prostate tissue. prostate cancer.  is Gleason grade 3, 4 and 5. Grade 5 is very different to normal tissue.

There may be more than 1 grade present in the biopsy. The doctor examines all the biopsy samples taken and identifies:

  • the most common grade
  • the highest other grade.

They add these together to give the Gleason score. For example, if the doctor finds the most common grade is 3 but the highest other grade seen in a sample is grade 4, then the Gleason score is 3 + 4 = 7.

Grade Group

The Grade Group is a number between 1 and 5. The lower the Grade Group, the less likely the cancer is to grow and spread.

Group 1 – Gleason score 6 (3+3)

The cancer cells look very similar to normal cells and are likely to grow very slowly, if at all.

Group 2 – Gleason score 7 (3+4)

Most of the cancer cells look like they will grow very slowly. Some may grow at a moderate rate.

Group 3 – Gleason score 7 (4+3)

Most of the cancer cells look like they will grow at a moderate rate. Some may grow very slowly.

Group 4 – Gleason score 8 (3+5, 4+4, 5+3)

The cancer cells look like they will grow at a moderately fast rate. Some may look like they will grow quickly.

Group 5 – Gleason scores 9 (4+5, 5+4) and 10 (5+5)

The cancer cells look like they will grow at a moderately fast rate or quickly.

Risk groups for prostate cancer

Prostate cancer can be described as low, intermediate or high risk.

Prostate cancer is also divided into 5 risk groups. Your doctor will look at:  

  • the T stage of the cancer
  • your Grade Group
  • your PSA level.

They can then identify a risk group. The Cambridge Prognostic Group (CPG) is a system that can help your doctors decide on the best treatment for you based on your risk. There are 5 risk group scores, from CPG1 to CPG5.

CPG 1

This means:

  • the cancer is T stage 1 or 2 and
  • the Grade Group is 1 and
  • the PSA is less than 10ng/ml.

The cancer is likely to grow very slowly and very unlikely to spread.

CPG 2

This means:

  • the cancer is T stage 1 or 2 and
  • the Grade Group is 2 or
  • the PSA is between 10 and 20 ng/ml.

The cancer is likely to grow slowly and is unlikely to spread.

CPG 3

This means:

  • the cancer is T stage 1 or 2 and
  • the Grade Group is 2 and
  • the PSA is between 10 and 20 ng/ml.

Or:

  • the cancer is T stage 1 or 2 and
  • the Grade Group is 3.

The cancer is more like to grow and spread outside the prostate.

CPG 4

This means:

  • the cancer is T stage 3 or
  • the Grade Group is 4 or
  • the PSA is more than 20ng/ml.

There is a higher risk of the cancer growing more quickly and spreading to another part of the body.

CPG 5

You are in this group if you have 2 or more of the following:

  • The cancer is T stage 3.
  • The Grade Group is 4.
  • The PSA is more than 20ng/ml.

You are also in this group if you have 1 of the following:

  • The cancer is T stage 4.
  • The Grade Group is 5.

There is a high risk of the cancer growing quickly and spreading to other parts of the body.

About our information

This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer.

  • References

    Below is a sample of the sources used in our prostate cancer information. If you would like more information about the sources we use, please contact us at informationproductionteam@macmillan.org.uk

     

    National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and management. NICE Guideline [NG131]. Published: 09 May 2019. Last updated: 15 December 2021. Available from: www.nice.org.uk/guidance/ng131 [accessed March 2024].

     

    Castro E, Fizazi K, Heidenreich A, Ost P, Parker C, Procopio G, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2020; 31(9): 1119–1134. Available from: www.annalsofoncology.org/article/S0923-7534(20)39898-7/fulltext [accessed March 2024].

Dr Ursula McGovern

Reviewer

Consultant Medical Oncologist & Honorary Associate Professor

University College Hospitals, London

Date reviewed

Reviewed: 01 October 2025
|
Next review: 01 October 2028
Trusted Information Creator - Patient Information Forum
Trusted Information Creator - Patient Information Forum

Our cancer information meets the PIF TICK quality mark.

This means it is easy to use, up-to-date and based on the latest evidence. Learn more about how we produce our information.

The language we use


We want everyone affected by cancer to feel our information is written for them.


We want our information to be as clear as possible. To do this, we try to:

  • use plain English
  • explain medical words
  • use short sentences
  • use illustrations to explain text
  • structure the information clearly
  • make sure important points are clear.

We use gender-inclusive language and talk to our readers as ‘you’ so that everyone feels included. Where clinically necessary we use the terms ‘men’ and ‘women’ or ‘male’ and ‘female’. For example, we do so when talking about parts of the body or mentioning statistics or research about who is affected.


You can read more about how we produce our information here.